Novel Therapeutic Strategies to Resolve Neurovascular Inflammation and Repair Blood-Brain Barrier Dysfunction in Epilepsy
解决癫痫神经血管炎症和修复血脑屏障功能障碍的新治疗策略
基本信息
- 批准号:10380864
- 负责人:
- 金额:$ 56.17万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-30 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:AgonistArachidonate 5-LipoxygenaseAttenuatedAutomobile DrivingBlood - brain barrier anatomyBlood brain barrier dysfunctionBlood capillariesBrain DiseasesCell Adhesion MoleculesCharacteristicsChronicClinicalCombined Modality TherapyDataData ReportingDevelopmentDiseaseEndotheliumEpilepsyExtracellular Matrix ProteinsExtravasationFPR2 geneFeedbackFunctional disorderFundingGlutamatesGoalsHumanIndividualInflammationInterventionKnockout MiceKnowledgeLOX geneLeadLearningLeukocytesLeukotrienesLinkLipoxygenaseMatrix MetalloproteinasesMediatingMissionModelingMolecular TargetMusNational Institute of Neurological Disorders and StrokeNeuronsPTGS2 genePathway interactionsPatientsProstaglandinsProteinsPublic HealthPublishingRattusResearchResearch PersonnelSeizuresSignal TransductionSymptomsTestingTherapeuticTherapeutic InterventionTight JunctionsUnited States National Institutes of Healthcerebral capillaryclinical translationcyclooxygenase 2evidence baseexpectationglutamatergic signalingimprovedin vivoinnovationmouse modelnervous system disorderneuroinflammationneurotransmitter releaseneurovascularnew therapeutic targetnovelnovel therapeutic interventionrepairedtherapy designtranslational potentialvascular inflammation
项目摘要
Blood-brain barrier dysfunction is recognized as both a cause and consequence of seizures in epilepsy. Two key
characteristics of barrier dysfunction in epilepsy include 1) neurovascular inflammation and 2) barrier leakage,
both of which have been linked to seizures. In spite of increasing evidence supporting that glutamate causes
blood-brain barrier dysfunction, knowledge of the associated underlying mechanisms remain to be fully defined.
Moreover, therapeutic options for restoring barrier function are currently not available. Thus, there is an unmet
critical need to determine how glutamate promotes blood-brain barrier inflammation and leakage and to develop
targeted strategies to restore barrier function. The consequence of this unmet need is that development of novel
treatments to improve seizure control in epilepsy will likely remain a clinical challenge. The long-term goal of the
investigator is to contribute toward the development of mechanism-based strategies to repair blood-brain barrier
dysfunction in brain diseases. The overall objective in this application is to establish the efficacy of a mechanism-
based intervention to treat blood-brain barrier dysfunction in epilepsy, thereby vertically extending what has been
learned under current funding. Based on preliminary data the central hypothesis of this project is that glutamate
signaling mediates blood-brain barrier dysfunction and that therapeutic intervention targeting this mechanism
will resolve seizure-induced neurovascular inflammation, repair barrier leakage, and reduce seizure burden. The
rationale for the proposed research is that its successful completion will provide a robust framework for the
continued development and clinical translation of a novel evidence-based therapeutic intervention to help treat
seizures in patients with epilepsy. The hypothesis will be tested by pursuing three specific aims: 1) Identify
signaling steps responsible for seizure-induced inflammation of the blood-brain barrier. 2) Determine the
mechanism responsible for capillary leakage at the human blood-brain barrier, and 3) Develop a therapeutic
intervention to reduce seizure burden in a chronic epilepsy model. Under Aim 1, signaling steps that lead to
seizure-mediated neuroinflammation will be determined in capillaries isolated from knockout mouse models and
verified in vivo. Under Aim 2, key signaling steps that trigger barrier leakage will be determined in human brain
capillaries from seizure-free control individuals and from patients with epilepsy. Under Aim 3, an intervention
therapy designed to repair barrier dysfunction will be developed and the therapeutic benefit of this strategy on
reducing seizure burden will be evaluated in a rat chronic epilepsy model. The proposed research is innovative,
because it represents a substantive departure from the status quo by shifting the focus to molecular targets at
the blood-brain barrier to resolve neurovascular inflammation, restore barrier function, and improve epilepsy
symptoms. The proposed research is significant because it holds the promise of a novel therapeutic approach
to repair barrier dysfunction that has translational potential for clinical use to advance treatment of patients with
epilepsy and other seizure disorders with underlying barrier dysfunction.
Blood-brain barrier dysfunction is recognized as both a cause and consequence of seizures in epilepsy. Two key
characteristics of barrier dysfunction in epilepsy include 1) neurovascular inflammation and 2) barrier leakage,
both of which have been linked to seizures. In spite of increasing evidence supporting that glutamate causes
blood-brain barrier dysfunction, knowledge of the associated underlying mechanisms remain to be fully defined.
Moreover, therapeutic options for restoring barrier function are currently not available. Thus, there is an unmet
critical need to determine how glutamate promotes blood-brain barrier inflammation and leakage and to develop
targeted strategies to restore barrier function. The consequence of this unmet need is that development of novel
treatments to improve seizure control in epilepsy will likely remain a clinical challenge. The long-term goal of the
investigator is to contribute toward the development of mechanism-based strategies to repair blood-brain barrier
dysfunction in brain diseases. The overall objective in this application is to establish the efficacy of a mechanism-
based intervention to treat blood-brain barrier dysfunction in epilepsy, thereby vertically extending what has been
learned under current funding. Based on preliminary data the central hypothesis of this project is that glutamate
signaling mediates blood-brain barrier dysfunction and that therapeutic intervention targeting this mechanism
will resolve seizure-induced neurovascular inflammation, repair barrier leakage, and reduce seizure burden. The
rationale for the proposed research is that its successful completion will provide a robust framework for the
continued development and clinical translation of a novel evidence-based therapeutic intervention to help treat
seizures in patients with epilepsy. The hypothesis will be tested by pursuing three specific aims: 1) Identify
signaling steps responsible for seizure-induced inflammation of the blood-brain barrier. 2) Determine the
mechanism responsible for capillary leakage at the human blood-brain barrier, and 3) Develop a therapeutic
intervention to reduce seizure burden in a chronic epilepsy model. Under Aim 1, signaling steps that lead to
seizure-mediated neuroinflammation will be determined in capillaries isolated from knockout mouse models and
verified in vivo. Under Aim 2, key signaling steps that trigger barrier leakage will be determined in human brain
capillaries from seizure-free control individuals and from patients with epilepsy. Under Aim 3, an intervention
therapy designed to repair barrier dysfunction will be developed and the therapeutic benefit of this strategy on
reducing seizure burden will be evaluated in a rat chronic epilepsy model. The proposed research is innovative,
because it represents a substantive departure from the status quo by shifting the focus to molecular targets at
the blood-brain barrier to resolve neurovascular inflammation, restore barrier function, and improve epilepsy
symptoms. The proposed research is significant because it holds the promise of a novel therapeutic approach
to repair barrier dysfunction that has translational potential for clinical use to advance treatment of patients with
epilepsy and other seizure disorders with underlying barrier dysfunction.
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Bjoern Bauer其他文献
Bjoern Bauer的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Bjoern Bauer', 18)}}的其他基金
Mechanism and Therapeutic Potential of CBD to Repair Blood-Brain Barrier Dysfunction in Epilepsy
CBD修复癫痫血脑屏障功能障碍的机制和治疗潜力
- 批准号:
10644405 - 财政年份:2023
- 资助金额:
$ 56.17万 - 项目类别:
Blood-Brain Barrier Repair in Alzheimer’s Disease with Epilepsy
阿尔茨海默病伴癫痫的血脑屏障修复
- 批准号:
10345905 - 财政年份:2022
- 资助金额:
$ 56.17万 - 项目类别:
Blood-Brain Barrier Repair in Alzheimer’s Disease with Epilepsy
阿尔茨海默病伴癫痫的血脑屏障修复
- 批准号:
10613906 - 财政年份:2022
- 资助金额:
$ 56.17万 - 项目类别:
A novel strategy to overcome the P-gp/BCRP drug efflux system at the blood-brain barrier to improve brain uptake of CNS therapeutics
克服血脑屏障处的 P-gp/BCRP 药物流出系统以改善中枢神经系统治疗药物的大脑摄取的新策略
- 批准号:
10225435 - 财政年份:2018
- 资助金额:
$ 56.17万 - 项目类别:
A novel strategy to overcome the P-gp/BCRP drug efflux system at the blood-brain barrier to improve brain uptake of CNS therapeutics
克服血脑屏障处的 P-gp/BCRP 药物流出系统以改善中枢神经系统治疗药物的大脑摄取的新策略
- 批准号:
9761586 - 财政年份:2018
- 资助金额:
$ 56.17万 - 项目类别:
A novel strategy to overcome the P-gp/BCRP drug efflux system at the blood-brain barrier to improve brain uptake of CNS therapeutics
克服血脑屏障处的 P-gp/BCRP 药物流出系统以改善中枢神经系统治疗药物的大脑摄取的新策略
- 批准号:
10452766 - 财政年份:2018
- 资助金额:
$ 56.17万 - 项目类别:
Blood-brain barrier function in epilepsy: new targets for therapy
癫痫中的血脑屏障功能:治疗的新目标
- 批准号:
8687756 - 财政年份:2012
- 资助金额:
$ 56.17万 - 项目类别:
Blood-brain barrier function in epilepsy: new targets for therapy
癫痫中的血脑屏障功能:治疗的新目标
- 批准号:
8887163 - 财政年份:2012
- 资助金额:
$ 56.17万 - 项目类别:
Blood-brain barrier function in epilepsy: new targets for therapy
癫痫中的血脑屏障功能:治疗的新目标
- 批准号:
9107249 - 财政年份:2012
- 资助金额:
$ 56.17万 - 项目类别:
Novel Therapeutic Strategies to Resolve Neurovascular Inflammation and Repair Blood-Brain Barrier Dysfunction in Epilepsy
解决癫痫神经血管炎症和修复血脑屏障功能障碍的新治疗策略
- 批准号:
9976832 - 财政年份:2012
- 资助金额:
$ 56.17万 - 项目类别:
相似海外基金
Parent-determined oral montelukast therapy for preschool wheeze with stratification for arachidonate-5-lipoxygenase
父母决定的口服孟鲁司特治疗学龄前喘息,并根据花生四烯酸 5 脂氧合酶分层
- 批准号:
MC_G1002451 - 财政年份:2010
- 资助金额:
$ 56.17万 - 项目类别:
Intramural
Development and application of a selective inhibitor of arachidonate 5-lipoxygenase
选择性花生四烯酸5-脂氧合酶抑制剂的研制及应用
- 批准号:
59870012 - 财政年份:1984
- 资助金额:
$ 56.17万 - 项目类别:
Grant-in-Aid for Developmental Scientific Research